This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Netflix ETFs to Buy on the Dip Post Solid Q1 Earnings
by Sweta Killa
Netflix (NFLX) topped both earnings and revenue estimates and delivered its strongest first-quarter customer additions since the pandemic. However, it issued disappointing second-quarter revenue guidance, which dragged the stock down.
What Lies in Store for Netflix ETF in Q1 Earnings?
by Sweta Killa
Netflix has risen about 26% over the past three months and has a reasonable chance to beat earnings estimates.
The Zacks Analyst Blog Highlights MicroSectors FANG+ ETN, Vanguard Communication Services ETF, Fidelity Disruptive Communications ETF, Pacer BioThreat Strategy ETF and First Trust S-Network Streaming & Gaming ETF
by Zacks Equity Research
MicroSectors FANG+ ETN, Vanguard Communication Services ETF, Fidelity Disruptive Communications ETF, Pacer BioThreat Strategy ETF and First Trust S-Network Streaming & Gaming ETF are included in this Analyst Blog.
ETFs to Buy on Netflix's Blowout Q3 Earnings
by Sweta Killa
Netflix topped both earnings and revenue estimates. It posted its best quarter in terms of subscriber growth in years.
What Lies in Store for Netflix ETF in Q3 Earnings?
by Sweta Killa
Netflix shares have plunged about 20% over the past three months amid the broad stock market weakness.
Social-Distancing ETFs Worth a Look As "Pirola" Covid Variant Spreads
by Sanghamitra Saha
A highly-mutated Covid-19 variant designated as BA.2.86, referred to as "Pirola," has surfaced and been detected in many countries.
ETFs to Add Gains on Netflix Q2 Solid Subscriber Growth
by Sweta Killa
Netflix (NFLX) topped earnings estimates while lagging on revenues. It also provided a downbeat revenue guidance.
Netflix Target Price Up Ahead of Q2 Earnings: ETFs in Focus
by Sweta Killa
Netflix shares rallied to their highest price in more than a year on Jul 17, after a series of analysts lifted the target price on the stock ahead of Q2 earnings.
ETFs to Click on Netflix's Mixed Q1 Results
by Sweta Killa
Netflix topped the earnings estimate while lagging on revenues. It also provided downbeat guidance.
What's in Store for Netflix ETFs in Q1?
by Sweta Killa
Netflix saw no earnings estimate revision over the past 30 days for the to-be-reported quarter. It's earnings surprise history is impressive.
ETFs to Click on Netflix's Blowout Q4 Subscriber Growth
by Sweta Killa
Netflix (NFLX) cheered investors as it easily surpassed the subscriber growth numbers but missed earnings estimates.
Netflix Set to Beat Q4 Earnings: ETFs to Buy
by Sweta Killa
Netflix has reasonable chances of an earnings beat and has positive earnings revisions, which are generally a precursor to an earnings beat ahead of its Q4 report.
Here's Why COVID-Themed ETFs May Come Back Under the Radar
by Sanghamitra Saha
COVID-themed stocks and ETFs were winners in 2020 and some parts of 2021 due to a spike in global coronavirus cases. We may see the same trend again as new COVID variants are 'pretty troublesome.'
Biothreat ETF (VIRS) Hits New 52-Week High
by Sanghamitra Saha
The Biothreat ETF hit a new 52-week high. Can it soar further?
Bet On COVID-Themed ETFs as New Cases Rise Globally
by Sweta Jaiswal, FRM
The remainder of 2021 is expected to continue reeling under the spurt in coronavirus cases. Thus, a COVID-themed ETF could be a wise choice.
ETFs to Buy as Squid Game Boosts Netflix Q3 Earnings
by Sweta Killa
After a disappointing first half of the year, Netflix (NFLX) reported solid third-quarter 2021 results wherein it beat on earnings and showed a pick-up in subscriber growth.
Netflix Looks Strong Ahead of Q3 Earnings: ETFs to Buy
by Sweta Killa
"Squid Game," the hyper-buzzy Korean drama debuted on Sep 17, seems to be a big game changer for Netflix in the quarter ending September.
The Zacks Analyst Blog Highlights: NURE, KCE, PHO, VCLO and VIRS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NURE, KCE, PHO, VCLO and VIRS
Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases
by Sweta Jaiswal, FRM
The remainder of 2021 is expected to continue reeling under the spurt in coronavirus cases. Thus, a COVID-themed ETF could be a wise choice.
Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan
by Sanghamitra Saha
The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.
5 Sector ETFs At All-Time Highs
by Sweta Killa
We have highlighted five ETFs from different sectors that hit new peaks in the recent trading session and have been the leaders in their respective sector so far this year.
Sanofi to Buy mRNA Developer: ETFs in Focus
by Sanghamitra Saha
Sanofi has agreed to acquire U.S. biotech company Translate Bio to gain exposure in the mRNA vaccine space.
Are COVID-Themed ETFs Back in Focus as Delta Variant Fears Rise?
by Sweta Jaiswal, FRM
The rest of 2021 is expected to continue bearing the brunt of the coronavirus outbreak. Thus, a COVID-themed ETF could be a smart pick.
Netflix Q2 Earnings Put These ETFs in Focus
by Sweta Killa
Netflix (NFLX) once again disappointed investors with lesser subscriber growth.
ETFs to Watch Ahead of Netflix Q2 Earnings
by Sweta Killa
After disappointing first-quarter earnings results, with lesser subscriber growth, investors are keen to watch whether Netflix managed to win subscribers in the second quarter amid stiff competition.